- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Zinbryta has been withdrawn at the request of the marketing authorisation holder.
Zinbryta : EPAR - Summary for the public
English (EN) (539.87 KB - PDF)
български (BG) (623.68 KB - PDF)
español (ES) (541.35 KB - PDF)
čeština (CS) (551.54 KB - PDF)
dansk (DA) (510.69 KB - PDF)
Deutsch (DE) (543.23 KB - PDF)
eesti keel (ET) (536.52 KB - PDF)
ελληνικά (EL) (628.44 KB - PDF)
français (FR) (542.84 KB - PDF)
hrvatski (HR) (559.5 KB - PDF)
italiano (IT) (536.25 KB - PDF)
latviešu valoda (LV) (588.49 KB - PDF)
lietuvių kalba (LT) (563.73 KB - PDF)
magyar (HU) (598.14 KB - PDF)
Malti (MT) (591.98 KB - PDF)
Nederlands (NL) (541.57 KB - PDF)
polski (PL) (606.49 KB - PDF)
português (PT) (541.48 KB - PDF)
română (RO) (565.84 KB - PDF)
slovenčina (SK) (588.64 KB - PDF)
slovenščina (SL) (582.09 KB - PDF)
Suomi (FI) (536.58 KB - PDF)
svenska (SV) (537.64 KB - PDF)
Product information
Zinbryta : EPAR - Product Information
English (EN) (1.27 MB - PDF)
български (BG) (2.25 MB - PDF)
español (ES) (1.32 MB - PDF)
čeština (CS) (2.16 MB - PDF)
dansk (DA) (1.31 MB - PDF)
Deutsch (DE) (1.41 MB - PDF)
eesti keel (ET) (1.23 MB - PDF)
ελληνικά (EL) (2.63 MB - PDF)
français (FR) (1.33 MB - PDF)
hrvatski (HR) (2.81 MB - PDF)
íslenska (IS) (1.08 MB - PDF)
italiano (IT) (1.09 MB - PDF)
latviešu valoda (LV) (1.88 MB - PDF)
lietuvių kalba (LT) (1.16 MB - PDF)
magyar (HU) (1.88 MB - PDF)
Malti (MT) (1.91 MB - PDF)
Nederlands (NL) (1.07 MB - PDF)
norsk (NO) (1.11 MB - PDF)
polski (PL) (1.87 MB - PDF)
português (PT) (1.09 MB - PDF)
română (RO) (1.22 MB - PDF)
slovenčina (SK) (1.86 MB - PDF)
slovenščina (SL) (1.88 MB - PDF)
Suomi (FI) (1.33 MB - PDF)
svenska (SV) (1.08 MB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zinbryta : EPAR - All Authorised presentations
English (EN) (477.64 KB - PDF)
български (BG) (517.25 KB - PDF)
español (ES) (481.09 KB - PDF)
čeština (CS) (488.17 KB - PDF)
dansk (DA) (459.95 KB - PDF)
Deutsch (DE) (479.68 KB - PDF)
eesti keel (ET) (483.13 KB - PDF)
ελληνικά (EL) (518.75 KB - PDF)
français (FR) (493.52 KB - PDF)
hrvatski (HR) (488.31 KB - PDF)
íslenska (IS) (481.38 KB - PDF)
italiano (IT) (481.24 KB - PDF)
latviešu valoda (LV) (511.88 KB - PDF)
lietuvių kalba (LT) (498.05 KB - PDF)
magyar (HU) (510.29 KB - PDF)
Malti (MT) (511.19 KB - PDF)
Nederlands (NL) (480.33 KB - PDF)
norsk (NO) (487.39 KB - PDF)
polski (PL) (525.13 KB - PDF)
português (PT) (480.86 KB - PDF)
română (RO) (498.61 KB - PDF)
slovenčina (SK) (508.81 KB - PDF)
slovenščina (SL) (37.55 KB - PDF)
Suomi (FI) (480.09 KB - PDF)
svenska (SV) (17.62 KB - PDF)
Product details
- Name of medicine
- Zinbryta
- Active substance
- daclizumab
- International non-proprietary name (INN) or common name
- daclizumab
- Therapeutic area (MeSH)
- Multiple Sclerosis
- Anatomical therapeutic chemical (ATC) code
- L04AC01
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
Authorisation details
- EMA product number
- EMEA/H/C/003862
- Marketing authorisation holder
- Biogen Idec Ltd
Innovation House
70 Norden Road
Maidenhead
Berkshire SL6 4AY
United Kingdom - Opinion adopted
- 31/03/2016
- Marketing authorisation issued
- 01/07/2016
- Revision
- 8
Assessment history
Zinbryta Article-20 referral - PRAC assessment report
English (EN) (241.57 KB - PDF)
Zinbryta Article-20 referral - PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage
English (EN) (193.2 KB - PDF)
Zinbryta : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (567.72 KB - PDF)
Zinbryta : EPAR - Scientific Conclusion
English (EN) (518.34 KB - PDF)
Zinbryta-H-A20-1456-C-3862-0010 : EPAR - Assessment Report - Article 20
English (EN) (847.17 KB - PDF)
News on Zinbryta
More information on Zinbryta
Clinical data (initial marketing authorisation)
Public statement on Zinbryta: Withdrawal of the marketing authorisation in the European Union
English (EN) (65.95 KB - PDF)